(Q40862556)

24 September 2017

title

Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. (English)

1 reference

24 September 2017

V Leroy

1

1 reference

24 September 2017

M Baud

2

1 reference

24 September 2017

C de Traversay

3

1 reference

24 September 2017

M Maynard-Muet

4

1 reference

24 September 2017

P Lebon

5

1 reference

24 September 2017

J P Zarski

6

1 reference

24 September 2017

language of work or name

1 reference

1 March 1998

1 reference

24 September 2017

published in

Journal of Hepatology

1 reference

24 September 2017

volume

28

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

375-381

1 reference

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Prevalence of breakthrough in chronic hepatitis C patients undergoing antiviral therapy: role of type and schedule of alpha interferon C.H.S.G.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Presence of an acid-labile alpha-interferon in sera from fetuses and children with congenital rubella

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

Selection of hepatitis C virus quasispecies during interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980309-7

7 January 2021

10.1016/S0168-8278(98)80309-7

Identifiers

DOI

1 reference

24 September 2017

1 reference